Matching articles for "Mirapex"
Issue 1618 · February 22, 2021
Drugs for Parkinson's Disease

The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused by…

Med Lett Drugs Ther. 2021 Feb 22; 63(1618):25-32
The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused by degeneration of other neurotransmitter systems. No disease-modifying drugs are available for treatment of PD.
Issue 1618 · February 22, 2021
Comparison Table: Drugs for Parkinson's Disease (online only)

View the Comparison Table: Drugs for Parkinson's Disease

Med Lett Drugs Ther. 2021 Feb 22; 63(1618):e1-9
View the Comparison Table: Drugs for Parkinson's Disease
Issue 1591 · February 10, 2020
Istradefylline (Nourianz) for Parkinson's Disease

The FDA has approved istradefylline ( Nourianz — Kyowa Kirin), an oral adenosine A 2A receptor antagonist, for use as an adjunct to carbidopa/levodopa in adults with Parkinson's disease (PD) who experience…

Med Lett Drugs Ther. 2020 Feb 10; 62(1591):20-3
The FDA has approved istradefylline ( Nourianz — Kyowa Kirin), an oral adenosine A 2A receptor antagonist, for use as an adjunct to carbidopa/levodopa in adults with Parkinson's disease (PD) who experience "off" episodes. Istradefylline is the first adenosine A 2A receptor antagonist to be approved in the US; it has been available in Japan since 2013.
Issue 1555 · September 10, 2018
Osmolex ER - Another Extended-Release Amantadine for Parkinson's Disease

The FDA has approved an extended-release tablet formulation of amantadine ( Osmolex ER – Vertical/Osmotica) for once-daily treatment of Parkinson's disease (PD) and drug-induced extrapyramidal symptoms (EPS)…

Med Lett Drugs Ther. 2018 Sep 10; 60(1555):148-50
The FDA has approved an extended-release tablet formulation of amantadine ( Osmolex ER – Vertical/Osmotica) for once-daily treatment of Parkinson's disease (PD) and drug-induced extrapyramidal symptoms (EPS) in adults. An extended-release capsule formulation of amantadine (Gocovri) was approved in 2017 for treatment of levodopa-induced dyskinesia in patients with PD.
Issue 1534 · November 20, 2017
Drugs for Parkinson's Disease

The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused by…

Med Lett Drugs Ther. 2017 Nov 20; 59(1534):187-94
The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused by degeneration of other neurotransmitter systems.
Issue 1534 · November 20, 2017
Comparison Table: Drugs for Parkinson's Disease (online only)

View the Comparison Table: Drugs for Parkinson's Disease

Med Lett Drugs Ther. 2017 Nov 20; 59(1534):e194-6
View the Comparison Table: Drugs for Parkinson's Disease
Issue 135 · November 1, 2013
Drugs for Parkinson's Disease

The motor symptoms of Parkinson's disease (PD) are caused primarily by progressive degeneration of dopaminergic neurons in the substantia nigra. The non-motor symptoms of the disease are thought to be caused…

Treat Guidel Med Lett. 2013 Nov; 11(135):101-6
The motor symptoms of Parkinson's disease (PD) are caused primarily by progressive degeneration of dopaminergic neurons in the substantia nigra. The non-motor symptoms of the disease are thought to be caused by degeneration of other neurotransmitter systems.
Issue 1397 · August 20, 2012 Free
In Brief: Transdermal Rotigotine (Neupro)

A patch formulation of the non-ergot dopamine agonist rotigotine ( Neupro – UCB) has returned to the US market after a 4-year absence. Originally approved by the FDA in 2007 for treatment of early…

Med Lett Drugs Ther. 2012 Aug 20; 54(1397):68
A patch formulation of the non-ergot dopamine agonist rotigotine ( Neupro – UCB) has returned to the US market after a 4-year absence. Originally approved by the FDA in 2007 for treatment of early Parkinson’s disease, 1 it was withdrawn in 2008 because of crystallization of the drug in the patch, which could have led to under-dosing. The new patch has somewhat broader indications than the old one; it is approved for use in any stage of Parkinson’s disease (PD) and also for moderate-to-severe restless legs syndrome (RLS). 1. Transdermal rotigotine (Neupro) for Parkinson’s disease. Med Lett Drugs Ther 2007; 49:69. Download complete U.S. English article
Issue 1372 · September 5, 2011
Gabapentin Enacarbil (Horizant) for Restless Legs Syndrome

Gabapentin enacarbil ( Horizant – GlaxoSmithKline), a new extended-release (ER) tablet formulation of gabapentin, has been approved by the FDA for treatment of moderate-to-severe restless legs syndrome…

Med Lett Drugs Ther. 2011 Sep 5; 53(1372):70-1
Gabapentin enacarbil ( Horizant – GlaxoSmithKline), a new extended-release (ER) tablet formulation of gabapentin, has been approved by the FDA for treatment of moderate-to-severe restless legs syndrome (RLS). The immediate-release (IR) formulation of gabapentin ( Neurontin ,and others), which is approved for treatment of epilepsy and postherpetic neuralgia, has been used for many years to treat RLS. Another ER tablet formulation of gabapentin (Gralise) has been approved by the FDA for treatment of postherpetic neuralgia.
Issue 101 · January 1, 2011
Drugs for Parkinson's Disease

Parkinson’s disease (PD) is caused primarily by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat PD because it does not cross the…

Treat Guidel Med Lett. 2011 Jan; 9(101):1-6
Parkinson’s disease (PD) is caused primarily by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat PD because it does not cross the blood-brain barrier.
Issue 62 · October 1, 2007
Drugs for Parkinson's Disease

ParkinsonÆs disease (PD) is caused primarily by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat PD because it does not cross the…

Treat Guidel Med Lett. 2007 Oct; 5(62):89-94
ParkinsonÆs disease (PD) is caused primarily by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat PD because it does not cross the bloodbrain barrier.
Issue 1268 · August 27, 2007
Transdermal Rotigotine (Neupro) for Parkinson's Disease

Rotigotine ( Neupro - Schwarz Pharma), a nonergot dopamine agonist in a transdermal patch formulation, was recently approved by the FDA for treatment of early Parkinson's disease (PD).

Med Lett Drugs Ther. 2007 Aug 27; 49(1268):69-70
Rotigotine ( Neupro - Schwarz Pharma), a nonergot dopamine agonist in a transdermal patch formulation, was recently approved by the FDA for treatment of early Parkinson's disease (PD).
Issue 1257 · March 26, 2007
Pramipexole (Mirapex) for Restless Leg Syndrome

The dopamine agonist pramipexole ( Mirapex - Boehringer Ingelheim) is the second drug approved by the FDA for treatment of moderate to severe restless legs syndrome (RLS). Ropinirole (Requip) , another…

Med Lett Drugs Ther. 2007 Mar 26; 49(1257):26-8
The dopamine agonist pramipexole ( Mirapex - Boehringer Ingelheim) is the second drug approved by the FDA for treatment of moderate to severe restless legs syndrome (RLS). Ropinirole (Requip) , another dopamine agonist, was approved for RLS in 2005. Both of these drugs were first approved for treatment of Parkinson's disease.
Issue 1214 · August 1, 2005
Ropinirole for Restless Legs Syndrome

Ropinirole ( Requip - GlaxoSmithKline), a dopamine agonist already available for treatment of Parkinson's disease, is now the first drug approved by the FDA for treatment of moderate to severe restless legs…

Med Lett Drugs Ther. 2005 Aug 1; 47(1214):62-4
Ropinirole ( Requip - GlaxoSmithKline), a dopamine agonist already available for treatment of Parkinson's disease, is now the first drug approved by the FDA for treatment of moderate to severe restless legs syndrome (RLS).
Issue 22 · June 1, 2004
Drugs for Parkinson's Disease

Parkinson's disease is caused by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat Parkinson's disease because it does not cross the…

Treat Guidel Med Lett. 2004 Jun; 2(22):41-6
Parkinson's disease is caused by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat Parkinson's disease because it does not cross the blood-brain barrier.
Issue 1108 · July 9, 2001
Initial Treatment of Parkinson's Disease:Wait Just a Minute

Recent articles in the press have trumpeted a new era in the management of Parkinson's disease: dopamine agonists have now replaced levodopa for initial treatment.

Med Lett Drugs Ther. 2001 Jul 9; 43(1108):59-60
Recent articles in the press have trumpeted a new era in the management of Parkinson's disease: dopamine agonists have now replaced levodopa for initial treatment.
Issue 1014 · November 21, 1997
Pramipexole and Ropinirole for Parkinson's Disease

Pramipexole (Mirapex - Pharmacia & Upjohn) and ropinirole (Requip - SmithKline Beecham), two new dopamine agonists, have been approved by the US Food and Drug Administration (FDA) for treatment of both early…

Med Lett Drugs Ther. 1997 Nov 21; 39(1014):109-10
Pramipexole (Mirapex - Pharmacia & Upjohn) and ropinirole (Requip - SmithKline Beecham), two new dopamine agonists, have been approved by the US Food and Drug Administration (FDA) for treatment of both early (without levodopa) and advanced (with levodopa) Parkinson's disease. Bromocriptine (Parlodel) and pergolide (Permax) are older dopamine agonists marketed in the USA for adjunctive use with levodopa.